首页> 外文期刊>Cytopathology >Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: A consecutive series of 267 patients
【24h】

Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: A consecutive series of 267 patients

机译:通过免疫组织化学和免疫细胞化学评估原发性乳腺癌中雌激素和孕激素受体状态的比较:连续系列267例患者

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The use of cytological specimens to evaluate tumour biomarkers in metastatic breast cancer lesions has attracted increased interest because of the considerable number of reports that have shown discordance between the primary tumour and metastatic lesion. Oestrogen receptor (ER) and progesterone receptor (PgR) assays are crucial for the management of patients with breast cancer, in both adjuvant and palliative settings. The aim of this study was to compare the ER and PgR immunocytochemical analysis of fine needle aspiration (FNA) samples with the immunohistochemistry (IHC) of surgical specimens and core biopsies from primary breast cancers. Methods: The FNA specimens were prepared as cell blocks (n=25) or ThinPreps (n=258) for the immunocytochemistry (IC) ER and PgR analyses. Sixteen patients were excluded because of lack of follow-up (n=1), neoadjuvant therapy (n=3) or cell counts in their fine needle aspirates that were too low (n=12). The results of IC on 25 cell blocks and 242 ThinPreps were compared with IHC on the corresponding core needle biopsies (n=16) or excised tumours (n=251). The ER and PgR status was defined as negative (when less than 10% of the nuclei were stained) or positive (when equal or more than 10% of the nuclei were stained). Kappa statistics were used to evaluate the concordance. Results: The ER concordance was 98% with ThinPrep (κ=0.93) and 92% with cell block (κ=0.82). The corresponding values for PgR were 96% (κ=0.91) and 96% (κ=0.92). Conclusions: Our results confirm that, in cases in which biopsies or surgical specimens are not available, IC (with either cell block or ThinPrep techniques) is a reliable method for the determination of the ER and PgR status performed under strict conditions using primary breast carcinomas, and is therefore potentially useful in metastatic settings.
机译:目的:使用细胞学标本评估转移性乳腺癌病变中的肿瘤生物标记物引起了越来越多的关注,因为大量报告显示原发性肿瘤与转移性病变之间存在矛盾。在辅助和姑息治疗中,雌激素受体(ER)和孕激素受体(PgR)测定对于乳腺癌患者的治疗至关重要。这项研究的目的是比较细针穿刺(FNA)样品的ER和PgR免疫细胞化学分析与原发性乳腺癌的手术标本和核心活检组织的免疫组织化学(IHC)。方法:将FNA标本制成细胞块(n = 25)或ThinPreps(n = 258),用于免疫细胞化学(IC)ER和PgR分析。由于缺乏随访(n = 1),新辅助治疗(n = 3)或细针穿刺细胞计数过低(n = 12),因此排除了16名患者。将25个细胞块和242个ThinPreps上的IC结果与相应核心针头活检(n = 16)或切除的肿瘤(n = 251)上的IHC进行了比较。 ER和PgR状态定义为阴性(当细胞核染色少于10%时)或阳性(当细胞核等于或大于10%染色时)。 Kappa统计数据用于评估一致性。结果:ThinPrep的ER一致性为98%(κ= 0.93),细胞阻滞的ER一致性为92%(κ= 0.82)。 PgR的相应值为96%(κ= 0.91)和96%(κ= 0.92)。结论:我们的结果证实,在无法获得活组织检查或手术标本的情况下,IC(采用细胞阻断或ThinPrep技术)是确定在严格条件下使用原发性乳腺癌进行的ER和PgR状况的可靠方法。 ,因此在转移设置中可能很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号